News Investors Nasdaq: LGND Home About Portfolio Summary Technologies Licensing Opportunities INVESTOR SUMMARY Overview Analysts FAQ COMPANY INFORMATION Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Protein Expression Technology® is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by more traditional systems. Ab Initio™ technology and services for the design and preparation of customized antigens enable the successful discovery of therapeutic antibodies against difficult-to-access cellular targets. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International. VIEW LATEST PRESENTATION LATEST NEWS Nov 9, 2021 Ligand Reports Third Quarter 2021 Financial Results Read more VIEW ALL NEWS LATEST FINANCIAL RESULTS Q3 2021 - Quarterly Results Ended Sep 30, 2021 PDF HTML Release AUDIO Earnings Webcast PDF HTML 10-Q Filing HTML Financials ZIP XLS HTML XBRL SIGN UP FOR EMAIL ALERTS Sign Up Today » STOCK SNAPSHOT NASDAQ: LGND Ligand Pharmaceuticals Incorporated Price/Change Volume Day Low/High Market Cap 52 Week Low/High CONTACT INFORMATION Investor Relations 5980 Horton Street Suite 405 Emeryville, CA 94608 T: 858-550-7500 investors@ligand.com Transfer Agent Computershare 462 South 4th Street Suite 1600 Louisville, KY 40202 T: 877-300-2100 © 2021 Ligand Pharmaceuticals Incorporated All Rights Reserved. Privacy Policy Disclaimer Sitemap